The team explored several alternative off-the-shelf or custom synthesized
ionophores with limited success. Ultimately, a chloride ion selective mem-
brane with outstanding selectivity and use-life was developed using com-
mon compounds available at a local hardware store. I use this example as a
reminder that sometimes we need to look outside of our area of expertise
to find the answer.
S100: It has been said that there hasn’t been a major advance in diagnostic sen-
sors since the MediSense glucose electrode in the mid 1980’s. Do you agree?
JS:Yes and no. It is true that self-monitored blood gluose testing is still king,
comprising 19% of the global IVD market. However, substantial progress
has been made in immunochemistry, point-of-care-diagnostics, hematology,
and molecular diagnostics in the areas of lower limit of detection, greater
specificity, faster time to result, lower sample volume, and decreased cost-
per-test.
For many diagnostic tests, however, there comes a point where there are
diminishing returns on pushing the envelope, so truly disruptive innovation
must expand beyond the aforementioned value propositions.This evolution
ushers in an exciting time for medical device manufacturers.
Jennifer Samproni
1...,5,6,7,8,9,10,11,12,13,14 16,17,18,19,20,21